Drug Database
ES

estradiol + gestodene (Successia / Successia 2 / Successia 1)

✓ Approved

Pfizer, Inc. · ESR1 · Small Molecule

What is estradiol + gestodene?

estradiol + gestodene is a small molecule developed by Pfizer, Inc.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesSuccessia, Successia 2, Successia 1
CompanyPfizer, Inc.
Drug ClassSmall Molecule
Molecular TargetESR1, PGR
RouteOral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

estradiol + gestodene acts on 2 molecular targets:

ESR1estrogen receptor 1 (ER, ESR)
PGRprogesterone receptor (NR3C3, PR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

estradiol + gestodene is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresHormone replacement therapy✓ Approved

Related Research Articles

PubMedPediatric endocrinology, diabetes, and metabolism2026-10-22

Association of physical activity, central adiposity, and fast-food consumption with 2-hour plasma glucose in adolescent girls at a boarding school in East Java.

Primadana Aditya A, Hermanto Adelia Lavenialita AL, Perwitasari Rayi Kurnia RK, Hisbiyah Yuni Y et al.

Type 2 diabetes mellitus (T2DM) is increasingly reported among adolescents and is associated with modifiable factors such as central obesity, physical inactivity, and frequent intake of fast food. Boarding schools offer a structured environment to assess these behaviours. To examine the correlation between physical activity, central adiposity, fast-food consumption, and 2-hour plasma glucose (2-hPG) in adolescent girls at a boarding school. A cross-sectional study was conducted among 127 adolescent girls in East Java. Physical activity was assessed using the Physical Activity Questionnaire for Adolescents. Adiposity was measured using body mass index (BMI) and waist circumference. Fast-food consumption frequency was recorded through a structured questionnaire. Blood glucose was measured using a 2-hPG test after oral glucose intake. Urine dipstick screening was also performed. Most participants had normal BMI, though 11.8% were overweight or obese. In total, 12.6% showed impaired glucose tolerance (IGT, 2-hPG 140-199 mg/dl) and had significantly larger waist circumference (p = 0.03). Waist circumference showed a non-significant correlation with 2-hPG (r = 0.041; p = 0.643); also, BMI showed no significant association with 2-hPG (r = 0.032; p = 0.723). Significant correlations were found between physical activity and 2-hPG (r = 0.205; p = 0.021), and between fast-food intake and BMI (r = -0.208; p = 0.020), although fast-food intake was not associated with 2-hPG (r = 0.038; p = 0.674). Early indicators of T2DM risk were identified. Although most associations were modest, increased waist circumference and reduced physical activity were associated with IGT, supporting the need for school-based lifestyle interventions.

PubMedBioconjugate chemistry2026-10-22

De Novo Design of a TROP-2-Targeting Peptide PET Tracer via AI-Guided Binding Interface Mimicry.

Lin Zefang Z, Yang Zhimin Z, Ma Sen S, Lin Xiuting X et al.

Trophoblast cell surface antigen 2 (TROP-2) is a transmembrane glycoprotein overexpressed across a range of epithelial malignancies, yet its clinical assessment still relies largely on invasive immunohistochemical analysis of biopsied tissues. In this study, we employed the PepMimic artificial intelligence platform to de novo design a TROP-2-targeting peptide, TR23, via binding interface mimicry, which was subsequently conjugated with DOTA and radiolabeled with 68Ga to yield the peptide-based PET probe [68Ga]Ga-DOTA-TR23. The tracer bound TROP-2 with nanomolar affinity (KD = 26.8 nM), showed selective cellular uptake in TROP-2-positive cells, and exhibited high radiochemical purity (>95%) with excellent stability in saline and serum. Micro-PET/CT imaging in pancreatic (BxPC-3), prostate (PC3), and thyroid (BCPAP) xenograft models revealed rapid, specific tumor accumulation with high contrast and low background uptake, while competitive blocking studies with excess unlabeled TR23 substantially suppressed tumor uptake, confirming receptor-mediated specificity. Quantitative analysis further demonstrated strong positive correlations between SUVmax and TROP-2 expression levels verified by immunohistochemistry across all three tumor types. Collectively, these findings establish [68Ga]Ga-DOTA-TR23 as a promising peptide-based PET tracer for rapid, specific, and quantitative imaging of TROP-2-positive tumors, and highlight the PepMimic-enabled strategy as a versatile platform for peptide-based probe discovery, supporting the translational potential of this tracer as a pan-cancer diagnostic agent for precision molecular imaging.

PubMedFrontiers in veterinary science2026-10-22

Assessment of radiographic healing after tibial plateau leveling osteotomy in young and older dogs using the modified RUST scoring system.

Anderson Bridget L BL, Frederick Steven W SW, Popovitch Catherine C

To compare radiographic osteotomy healing scores after tibial plateau leveling osteotomy (TPLO) in young (2-5 years) and old (8-12 years) dogs using the modified Radiographic Union Score for Tibial fractures (mRUST) system, and to evaluate agreement between large language model-assisted interpretation (LLM), surgeon, and surgical resident scoring. Client-owned, 20-40 kg dogs treated with unilateral TPLO at ages 2-5 or 8-12 years between 2023 and 2025 were retrospectively identified. Dogs with endocrinopathy or atypical TPLO or recovery were excluded. Dogs were assigned to Group 1 (2-5 years) or Group 2 (8-12 years). 8-week postoperative radiographs were scored independently by an LLM, a surgeon, and a surgical resident using the 4-point mRUST system. Scores were compared between age groups using the Wilcoxon rank-sum test, and interrater agreement was assessed using an intraclass correlation coefficient (ICC). Group 1 had 49 dogs; Group 2 had 51 dogs. Group 1 had a mean (SD) age of 3.82 (1.11) years, while Group 2 had a mean (SD) age of 9.24 (0.99) years. mRUST scores did not differ between age groups across LLM (p = 0.352), surgeon (p = 0.908), or resident assessments (p = 0.588). LLM, surgeon, and resident scores had only fair agreement (ICC = 0.4504, p < 0.001). Chronological age was not associated with mRUST score following TPLO at the 8-week postoperative evaluation. The mRUST system demonstrated moderate agreement between human observers. LLM scoring showed promise; further refinement is needed for clinical application.

PubMedKidney research and clinical practice2026-10-22

Clinical effects of third doses of mRNA COVID-19 vaccines among hemodialysis patients: a nationwide retrospective cohort study.

Cho AJin A, Jeong Seon A SA, Seo Yu Bin YB, Park Hayne Cho HC et al.

Evidence on the effectiveness of third-dose messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccination during the Omicron-dominant period in Asian hemodialysis (HD) patients remains limited. We evaluated the clinical effectiveness of a third mRNA vaccine dose against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hospitalization, and mortality in Korean HD patients. Using the Korea Disease Control and Prevention Agency-National Health Insurance Service database, we conducted a nationwide cohort study of HD patients aged ≥18 years who received two or three doses of BNT162b2 or mRNA-1273 before January 16, 2022. Study outcomes were SARS-CoV-2 infection, hospitalization, and death. Cox proportional hazards models were used to assess the associations between third-dose vaccination and clinical outcomes. Among 66,389 HD patients (mean age, 65.7 ± 12.9 years; 60.5% male), 55,125 (83.0%) received three vaccine doses and 11,264 (17.0%) received two doses. Receipt of three doses was associated with a significantly lower risk of SARS-CoV-2 infection (adjusted hazard ratio [aHR], 0.58; 95% confidence interval [CI], 0.56-0.60). Among 17,886 patients with SARS-CoV-2 infection, third-dose vaccine recipients had a lower risk of hospitalization (aHR, 0.65; 95% CI, 0.62-0.70) and 30-day mortality (aHR, 0.35; 95% CI, 0.30-0.41) compared with those who received two doses. Receipt of mRNA-1273 as the third dose was associated with lower observed risks of infection and hospitalization than receipt of BNT162b2. A third dose of an mRNA COVID-19 vaccine was associated with lower risks of SARS-CoV-2 infection, hospitalization, and mortality among HD patients during the Omicron-dominant period. These findings support the clinical importance of booster vaccination in this high-risk population.

PubMedDalton transactions (Cambridge, England : 2003)2026-10-22

Stability and quantum tunnelling in the intramolecular proton transfer of molybdic acid.

Santoyo-Flores Juan Julian JJ, Ben-Eliyahu Yeshayahu Y, Kozuch Sebastian S

We explored with computational means the stability and interconversion kinetics of several possible molybdenum complexes in neutral or slightly acidic media, including, among others, [MoO(OH)4(H2O)], [MoO2(OH)2(H2O)2], [MoO(OH)4], and [MoO3(H2O)]. These complexes are related through three kinds of intramolecular proton-transfer reactions, allowing one complex to convert to another. In particular, we analysed the role of quantum tunnelling at low and high temperatures, with and without an explicit water molecule catalysing the reactions through a Grotthuss type of proton shuttle mechanism. We identified [MoO2(OH)2(H2O)2], compound 4, as the most stable structure, in line with previous studies. At room temperature all the interconversions are fast, allowing the system to readily reach compound 4 from every other possible complex; under these conditions, thermally activated tunnelling is a measurable but small factor. However, our results indicate that at low temperatures tunnelling is the only plausible mechanism for the reaction, permitting fast rearrangements to reach compound 4 even in the absence of enough thermal energy to overcome the barriers.

PubMedRevue medicale suisse2026-10-22

[Nightmare or wonder : a bat on the ceiling].

Ménard Agathe A, Erard Véronique V

Rabies is an invariably fatal zoonosis in humans caused by a neurotropic virus of Lyssavirus genus. Three genotypes are endemic in Europe. Genotype 1 or RABV (Rabies lyssavirus) is the agent of classical rabies, for which dogs and certain wild carnivores serve as reservoirs; genotypes 5 and 6, respectively EBLV-1 and EBLV-2 (European bat lyssavirus type 1 and 2), have bats as reservoirs. In Switzerland, classical rabies (RABV) has been eradicated since 1999, a status shared by the majority of European Union countries. Cases of human rabies encephalitis transmitted by bats in Europe are associated with EBLV-1 and EBLV-2 but are exceptional. This article aims to present the epidemiology, pathogenesis and prevention of rabies in Switzerland.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about estradiol + gestodene